Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination With Atezolizumab in Patients With Selected Advanced/Metastatic EGFR-expressing Cancers

NCT05109442 is registered in ClinicalTrials.gov with Affimed GmbH as lead sponsor.

NCT NCT05109442
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05109442 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination With Atezolizumab in Patients With Selected Advanced/Metastatic EGFR-expressing Cancers
Lead sponsor
Affimed GmbH
Phase
Phase 1/2
Overall status
Terminated
Start date
November 19, 2021
Completion date
June 11, 2025
Enrollment
112 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor